

# INDEX

---

## A

Abdominal striae, 195  
ACNU, *See* Nimustine  
ACTIVATE trial, 185–186  
Adamantinomatous  
    craniopharyngiomas, 78, 80  
Addisonian crisis, 194  
Adenocarcinomas, 233, 234, 246, 287  
Adenovirus infection, 306  
Adrenocorticotrophic hormone  
    (ACTH), 148, 193–194,  
    197–199, 207–208, 221  
Adrenocorticotrophic hormone-  
    secreting adenomas, 195,  
    206–209, 211f, 214  
AEE788 compound, use in treating  
    gliomas, 176–177  
Aneurysmal bone cysts, 278–279  
Angiitis, 303t, 325t  
Angiography, 87, 277, 279, 288, 304  
    catheter, 50  
    cerebral, 50  
    CT, 38–40  
    MRI, 42  
    spinal, 277  
Antibody-guided therapy, 184–185  
Anti-CD68 antibody, 33  
Anti-HAM56 antibody, 33  
Antihistamines, as cause of  
    meningiomas, 14, 20  
Anti-phosphohistone H3 (pHH3)  
    antibody, 29, 29f  
Antiphospholipid antibody  
    syndrome, 303t  
Antiprogestosterone agents, 57  
Ara-C, *See* Cytarabine

Arachnoiditis, 81, 257  
Ashkenazi Jews, incidence of  
    breast cancer brain metastases  
    in, 235  
Astrocytomas, 97f, 143, 145–146,  
    307, 309, 311  
    anaplastic, 45f, 163–165, 173  
    pilocytic, 7t, 32, 94, 109–116,  
    109–111f, 145, 307  
    pilomyxoid, 30  
Astroglial variants of gliomas  
    clinical features, 109–110  
    histopathologic characteristics,  
    112–113  
    neuroimaging features, 111–112  
    therapeutic options, 114–116

## B

B-cell antigens, 265  
BCNU, *See* Carmustine  
Beevor's sign, 275  
Behçet' syndrome, 303t, 325t  
Bevacizumab, use in treating  
    glioblastomas, 163  
Biopsy tissue, handling of  
    cytologic specimens, 26–27  
    formalin-fixed, paraffin-  
    embedded tissue sections, 28  
    frozen tissue sections, 27  
    tissue for ultrastructural  
    examination, 28  
Blood-brain barrier, 41–42, 155–156,  
    181, 199, 237, 247, 267  
Blood transfusion, during  
    surgery, 288  
Bracing, of spine after surgery, 292

- Bragg peak, 141  
*BRCA* gene, 235  
 Broca's motor speech area, 128  
 Bromocriptine, 202, 204, 210, 212  
 Brown-Séquard syndrome, 275, 318  
 Busulfan, use in treating PCNSL, 269–270
- C**  
 Cabergoline, 202, 204, 212  
 Capecitabine, 163, 174  
 Carbamazepine, 156, 335  
 Carboplatin, 161–163, 165, 174, 233  
 Carcinoembryonic antigen, 253, 300t  
 Carmustine (BCNU), 142, 160–164, 173, 179, *See also* Gliadel wafers  
 Cauda equina lesions, 305, 324  
   causes of, 325–326t  
   diagnostic tests for, 325–326t  
 Cauda equina syndrome, 275  
 CCNU, *See* Lomustine  
*CDKN2* tumor suppressor gene, 56, 172  
 Cell saving, during surgery, 288  
 Cellular immunotherapy, 182–184  
 Cellular telephone use, and brain tumors, 16–17  
 Central Brain Tumor Registry of the United States (CBTRUS), 3–6  
 Central nervous system (CNS) neoplasms, *See* Intradural spinal tumors  
 Central neurocytomas, 30, 32  
*c-erb* oncogene, 56–57  
 Cerebrospinal fluid (CSF) analysis, 250, 252–253  
 Cervical spondylarthropathy, 298  
 Chemotherapy, 106–108, 116, 125, 132, 144, 156, 214, 217, 281, 292  
   adjuvant, 66, 107, 292, 334–335  
   for anaplastic astrocytomas, 163–166, 173  
   for anaplastic oligodendrogliomas, 165–166  
   for astroglial variants, 116  
   for glioblastomas, 159–163  
   for high-grade gliomas, 173–174  
   with immunotherapy, 186  
   intrathecal (IT), 255–257, 270  
   for low-grade gliomas, 106–108, 108t, 166–167  
   methotrexate-based, 267–268, 303t  
   for neoplastic meningitis, 257  
   for oligodendrogliomas, 30, 99  
   for PNETs, 143–144  
   for SLCL metastases, 233  
 Choline-to-creatine ratio, 45–46, 45–46f  
 Chondrosarcomas, 282–284, 283f  
 Chordoid gliomas, 30, 32  
 Chordomas, 12, 281–282  
 Choroid plexus papillomas  
   clinical presentation, 84–85  
   diagnostic imaging, 85, 85f  
   epidemiology, 84  
   etiology, 84  
   management, 86  
 Churg-Strauss syndrome, 303t  
 Cisplatin, 116, 160, 162, 164, 233  
 Clinically nonfunctional  
   adenomas, 193–194, 196, 199, 210–212, 214  
 Collimators, 136–139, 137f, 139f  
 Computed tomography (CT)  
   angiography and venography, 38–40, 39–40f  
   of astroglial variants, 111–112  
   CT-guided needle biopsy, 276  
   as diagnostic tool, 279–280, 300t, 304–305, 325t  
   of epidermoid and dermoid cysts, 83  
   of hemangioblastomas, 87  
   information bias of, 155

- of low-grade gliomas, 96, 100
  - for lung cancer, 232
  - of meningiomas, 59, 64
  - of metastatic brain tumors, 227
  - of PCNSL, 264
  - perfusion, 40–41, 41f
  - of schwannomas, 68–71
  - of spinal tumors, 276–278
  - vs MRI, 96, 251–252
  - Conus medullaris syndrome, 275
  - Corticotropin, *See*
    - Adrenocorticotrophic hormone
  - Cranial nerve dysfunctions, 73–77, 213
  - Craniopharyngiomas, 218–219
    - clinical presentation of, 78
    - cystic, 80
    - diagnostic imaging of, 79, 79f
    - epidemiology of, 77
    - etiology of, 77–78
    - management of, 80–81
    - pathology of, 80
    - squamous-papillary, 80
  - Cranioplasty, 63
  - Crohn's disease, 304
  - Cryptococcosis, 302t
  - Cryptococcus, as cause of
    - myelopathy, 306
  - CTP-11, *See* Irinotecan
  - Cushing's disease, 193, 195, 198–199, 207–209, 221
  - Cyclophosphamide, use in treating
    - PCNSL, 266, 269–270
  - Cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD), 267
  - Cytarabine (Ara-C), 255–257, 267, 269–270
  - Cytochrome p450, 13t, 156
  - Cytochrome p450 (CYP2D6) gene, 15
  - Cytologic techniques,
    - intraoperative, 27t
  - Cytomegalovirus, 303t, 306, 326
- D**
- Dacarbazine, use in treating
    - meningiomas, 66
  - Deep vein thrombosis prophylaxis and anticoagulation, use of
    - after surgery, 292
  - DepoCyt, *See* Cytarabine
  - Dermoid cysts, *See* Epidermoid and dermoid cysts
  - Diabetes insipidus, 78, 80–81, 195, 198, 215, 249t
  - Diabetes mellitus, 125, 195, 198, 206
  - Diagnosis, of CNS tumors
    - errors in, 31–33, 32t
    - tools for, 6, 26, 38–50, 59–61, 68–70, 79, 85, 87, 250–253
  - Diaziquone, use in treating
    - neoplastic meningitis, 256
  - Diffuse low-grade gliomas, 33, 116
    - clinical features, 95
    - histopathologic characteristics, 96–98
    - molecular profiles, 98–99
    - neuroimaging features, 96
    - prognostic factors, 99–100
    - therapeutic options, 100–108
  - Diplopia, 59, 74, 77, 196–197, 215, 247, 304
  - Distal sacral tumors, 291
  - Diuretics, effect on cancer
    - incidence, 14, 20
  - Doxorubicin, 66, 266–267
  - Dysembryoplastic neuroepithelial tumors, 30, 32
- E**
- Eastern Cooperative Oncology Group (ECOG), 142, 160, 165
  - EGFRvIII antigen, 174, 176, 182, 185–186
  - Electromagnetic fields, effect on
    - cancer incidence, 13t, 16
  - Electrophysiologic monitoring, use during surgery, 288

- Embolization, 50, 87, 277–279, 281–282, 287–288
- Encephalopathy, 258, 269, 334, 339
- Endocrinopathy, 78–81, 148
- Endoscopy, use in resecting pituitary tumors, 200
- Ependymomas, 11, 247, 304, 307, 309, 311–313, 315
- Epidemiology, of brain tumors
- age differences, 4–7f, 6–8, 7t
  - ethnicity, 8–9, 9f
  - genetic susceptibility and familial aggregation, 12–15, 13t
  - geographic variations, 8–10
  - incidence rates, 3–6, 6–7f, 8–10, 9f
  - infectious agents and immunologic response, 14t, 20–21
  - ionizing and non-ionizing radiation, 13t, 15–17
  - lifestyle factors, 13t, 14, 18–19
  - medical history and medication use, 14, 14t, 19–20
  - mortality and survival rates, 4–6, 4–6f, 158t
  - occupational exposure, 13t, 17–18
  - sex differences, 8
- Epidermal growth factor receptor (*EGFR*) allele, 10–11, 30–31
- Epidermal growth factor receptor (*HER2*), 236–237
- Epidermoid and dermoid cysts
- clinical presentation, 82
  - diagnostic imaging, 83–84
  - epidemiology, 81–82
  - etiology and pathogenesis, 82
  - management, 84
- Epidural lipomatosis, 301t
- Epstein-Barr virus, 264, 297, 303t, 326
- Erlotinib, use in treating GBM, 163, 176
- Etoposide, 160–161, 163–165, 233, 269–270
- European Organization for Research and Treatment of Cancer (EORTC), 99–100, 104, 106–108, 108t, 161, 165, 173
- Ewing's sarcomas, 282
- Extradural spinal tumors
- adjuvant therapies for, 291–292
  - bony spinal lesions, 277–284
  - clinical presentation of, 275
  - diagnostic tests for, 275–277
  - indications for surgery, 287
  - metastatic spinal lesions, 284–287, 285–286f
  - postoperative care for, 292
  - surgical adjuncts for, 288
  - surgical techniques for, 288–291
- Extramedullary tumors
- clinical presentation, 318
  - diagnostic imaging, 319
  - incidence and etiology, 316–318
  - surgical treatment, 319–324
- F**
- Facetectomy, 319–321
- Fertility, effect of excess hormone secretion on, 194–196, 199
- $\alpha$ -Fetoprotein, as marker of neoplastic meningitis, 253
- Fibrocartilaginous embolism, 301t
- Fluoroscopy, during surgery, 288
- Folinic acid, 256–257
- Follicle-stimulating hormone (FSH), 193–194, 196, 210, 212
- Foster-Kennedy syndrome, 59
- Fried egg cytologic appearance, 97
- Fungal infections, 302t, 305, 325t
- G**
- Gadolinium enhancement, *See* Magnetic resonance imaging
- Gangliogliomas, 11, 95, 109–110, 113
- Gefitinib, use in treating gliomas, 176
- Germinomas, 144

- Giant cell tumors, 280–281
- Gliadel wafers, 161–162, 179, *See also* Carmustine
- Glial fibrillary acidic protein (GFAP), 28, 97, 113
- Glioblastoma multiforme (GBM), 48f, 123–124, 123–124t, 126f, 156–159, 172, 191, 252f, 332  
chemotherapy for, 159–163, 173  
immunotherapy for, 182, 184–185  
signal transduction inhibitors for, 175–177
- Glioblastomas, 7t, 25, 31, 112–113, 124, 130f, 184, 332  
chemotherapy for, 108, 159–163, 160–161t, 163t  
epidemiology of, 4–7, 10
- Gliomas, 10, 14, 20, 33, 129f, 304, *See also* Diffuse low-grade gliomas; High-grade gliomas; Low-grade gliomas
- Glutathione transferase  $\theta$  (*GSTT1*) gene, effect on tumor incidence, 15
- Gonadotropin-secreting tumors, 195, 210, 212, 214
- GP240 antigen, use in treating gliomas, 172
- Growth hormone (GH), 148, 193, 195, 199, 214
- Growth hormone-secreting adenomas, 204–207, 213–214, 219
- H**
- Headache, 78, 87, 95, 147, 197, 215, 228, 236, 239, 247, 256, 331, 344–347
- Hemangioblastomas, 32, 50, 307–309, 311, 313  
clinical presentation, 87  
diagnostic imaging, 87  
epidemiology and genetics, 86–87  
management, 87–89
- Hemangiomas, 278
- Hemorrhage, 38, 42, 59, 197, 230–231, 239–240, 278–279, 304, 308, 319
- Hemostasis, during surgery, 129, 310, 313
- Henoch-Schönlein purpura, 303t
- Herpesvirus infection, as cause of brain tumors, 264, 300t, 302t, 305–306
- High-grade gliomas  
chemotherapy for, 173–174  
classification and characteristics of, 121–122  
decision to resect, 122–125  
diagnostic imaging of, 178f  
drug delivery techniques for, 179  
immunotherapy for, 179–186, 180t, 183t  
signal transduction inhibitors for, 174–179  
survival after surgery, 124t  
surgical approaches for, 125–132  
targets of, 174
- Histology, of brain tumors, *See* individual tumor types and WHO classification system
- Histoplasmosis, 306
- $\beta$ -Human chorionic gonadotropin, as marker of neoplastic meningitis, 253
- Human immunodeficiency virus infection, 306
- Hydroxyurea, 66, 163–165, 176
- Hypertension, 77, 125, 195, 206
- Hyperthyroidism, 195, 209–210
- Hypopituitarism, 147, 192, 203, 208–211, 215
- Hypothyroidism, 78, 80, 210, 304
- Hypoxia-inducible factor-1 (HIF-1), effect on brain tumor incidence, 86–87

- I**
- Idiopathic transverse myelitis, 301t
  - Immunoglobulin, 180, 265, 281, 303t, 305
  - Immunohistochemical markers, of brain tumors, 28–29
  - Insulin-like growth factor I (IGF-I), 58, 195, 197, 204–206, 221
  - Interleukin, use in cancer therapy, 179, 182, 184, 257
  - Intracranial germ cell tumors, 144
  - Intradural spinal tumors, *See also* Extramedullary tumors
    - diagnostic imaging, 304–305
    - diagnostic workup, 298–299, 298–299f, 300–303t
    - incidence and mortality rates, 3–5
    - patient history and physical examination, 299–304
    - serum and CSF tests, 305–306
    - therapeutic interventions, 306–307
  - Intramedullary tumors
    - clinical presentation, 308
    - diagnostic imaging, 308–309, 312f
    - incidence and etiology, 307–308
    - surgical treatment, 309–316, 312f
  - Intraoperative fluoroscopy, 288, 314f
  - Irinotecan (CPT-11), use in treating recurrent tumors, 162–163, 165, 174
- J**
- Janus kinase (Jak)/STAT pathway, 174, 175f
  - Juvenile nasal angiofibromas, 50
- K**
- Karnofsky performance scale (KPS), 123, 158, 158t, 185, 228, 234, 240–241, 254, 258, 336
  - Ki-67 antigen, 29, 67
  - Kohlmeier-Degos syndrome, 303t
  - Kyphoplasty, 289–290
- L**
- Laryngeal mask intubation, 127
  - Leptomeningeal disease, 236, 254, 270, 318, 337
  - Leptomeninges, 54, 113, 246–247, 255, 264, 270
  - Leukoencephalopathy, 147–148, 257, 334
  - Lhermitte's sign, 147
  - Li-Fraumeni syndrome, 13t, 14
  - Lipomas, 308, 310
  - Lomustine (CCNU), 107, 116, 162–163, 165, 173, 177, 214, 270
  - Loss of heterozygosity (LOH), 10–12, 30, 56–57, 68, 94, 96f, 98–101, 106–108, 156, 159, 165–167, 172
  - Low-grade gliomas
    - astroglial variants (circumscribed), 108–116
    - chemotherapy for, 108t, 166–167
    - classification and characterization of, 94, 94t
  - Luteinizing hormone (LH), 193–194, 196–197, 210, 212
  - Lyme disease, 302t, 325t
- M**
- Mafosfamide, use in treating neoplastic meningitis, 256
  - Magnetic resonance imaging (MRI)
    - advantages of, 6, 41, 102, 102f, 193, 198–199, 226, 251, 264, 297, 305
    - angiography and venography, 42, 43f
    - of astroglial variants, 111–112
    - as diagnostic tool, 276–277, 300t, 304, 325t
    - fluid-attenuated inversion recovery (FLAIR), 41–42, 83, 83f, 129f, 228

- functional, 47, 49f
- gadolinium enhancement, use
  - of, 41–42, 47, 70, 96, 112, 177, 178f, 199, 228, 239, 251–253f, 264, 277, 308, 319
- information bias of, 155
- of low-grade gliomas, 95
- maximum intensity projection and volume rendering, 42
- of meningiomas, 59–61, 59–60f, 64, 146
- of PCNSL, 264
- perfusion imaging, 47, 48f
- of radiation necrosis, 149
- relaxation time, 41
- of schwannomas, 68–71
- spectroscopy, 44–47, 44–46f
- of spinal tumors, 276–277
- of tumor vascular perfusion, 177–178
- T1-weighted images, 41–42, 59–60, 87, 228, 309
- T2-weighted images, 41–42, 60–61, 228, 309
- vs CT, 79, 251–252
- Major histocompatibility complex (MHC), 180
- Marimastat, 162, 176
- McCune-Albright syndrome, 220
- McGill Pain Questionnaire, 343
- Medulloblastomas, 7–8, 7t, 11, 64f, 143–144
- Meningiomas, 7t, 11, 16, 20, 25, 50, 54, 146, 317, 319, 321
  - clinical presentation, 58–59
  - common sites and incidence in adults, 55, 55t
  - diagnostic imaging, 39–40f, 59–61, 64, 146
  - epidemiology, 55
  - etiology, 55–58
  - management, 62–66
  - pathologic subtypes, 61–62
  - recurrence, 66–67
- Meningitis, 82, 256, 302t, 305, 325t,
  - See also* Neoplastic meningitis
- Meningomyelitis, 302t
- MERLIN protein, 56, 68
- Metaplastic theory, 78
- Metastases to the brain, 144–145
  - from breast cancer, 235–238, 286
  - from lung cancer, 232–235
  - from malignant melanoma, 238–240, 239f, 288
  - from renal cell carcinoma, 231, 287–288
  - from thyroid carcinoma, 288
- Metastases to the spine, 145, 253f
- Methotrexate (MTX), 148, 255–257, 267–271, 303t
- Methyl methacrylate injections, 285f, 289
- MGMT, *See* O<sup>6</sup>-methylguanine-DNA methyltransferase
- MIB-1 labeling index, 213
- $\beta_2$ -Microglobulin, 180, 253, 265, 325t
- Mifepristone, use in treating meningiomas, 57, 66
- Mixed cryoglobulinemias, 303t
- Monoclonal antibody 81C6, 184–185
- Monomorphous angiocentric bipolar gliomas, 30
- Multidrug resistance (*MDR*) gene, 155
- Multifocal neuraxis symptoms, 304
- Multiple endocrine neoplasia type 1 (*MEN1*), 219–221
- Multiple sclerosis, 298, 300t, 302t, 305
- Mycoplasma-associated myelitis, 302t
- Myelopathy, 305–306
  - disease-associated causes and evaluations, 301–303t
  - signs, symptoms, and diagnostic tests, 300–301t
- Myxedema, 194

- Myxopapillary ependymomas of the filum terminale, 25, 32, 317–318, 321–323, 322–323f
- N**
- N*-Acetylaspartate (NAA), 44–45, 44f, 61
- National Association of Brain Tumor Consortium (NABTC), 174, 176, 178
- Neoplasia, 300t
- Neoplastic meningitis (NM)  
 diagnosis, 247–253, 248f, 249t  
 epidemiology, 246–247  
 management, 253–258  
 pathophysiology, 247  
 prognosis, 258–259, 258–259t  
 treatment, 259
- Nerve block, for pain management, 348
- Nerve sheath tumors, 7t, 67, 316–317, 319–321
- Neuraxial analgesia, for pain management, 347–348
- Neurocognitive deficit, due to radiotherapy, 148
- Neurocognitive dysfunction  
 assessment of, 335–338  
 pharmacologic and psychologic management of, 338–341  
 variables contributing to, 331–335
- Neurocognitive functioning  
 assessment of, 335, 337  
 variables contributing to, 333–334, 339
- Neuroendocrine dysfunction, due to radiotherapy, 148
- Neurofibromas, 317
- Neurofibromatosis (NF), 13t, 14, 55, 68, 317  
 type 1 (NF1), 13t, 14, 317  
 type 2 (NF2), 13t, 14, 55, 67–68, 317
- Neuromodulation, for pain management, 348
- Neuromyelitis optica, 302t, 306
- Nevoid basal cell carcinoma syndrome, 13t, 14
- Nimustine (ACNU), 256
- Nitrosourea, use in treating glioblastomas, 162–165
- N*-Nitroso compounds, effect on cancer incidence, 13t, 18–19
- Non-small cell lung carcinoma (NSCLC), 232–234
- North American Brain Tumor Consortium (NABTC), 157, 162
- North Central Cancer Treatment Group (NCCTG), 104, 157, 164–165
- Null cell adenomas, 194, 210
- O**
- Octreotide, use in treating hormone-secreting tumors, 204, 210
- Oligodendrogliomas, 10–11, 46f, 49f, 94–99, 96f, 101, 107–108, 173  
 anaplastic, 98–99, 107, 165–166
- O<sup>6</sup>-Methylguanine-DNA methyltransferase (MGMT), 31, 157, 159
- Oncostatin M, expression in meningiomas, 58
- Opioids, use in pain management, 347
- Osteoblastic lesions, 279–280
- Osteoblastomas, 279–280
- Osteochondromas, 280
- Osteoid osteomas, 279–280
- Osteoporosis, 195, 199
- Osteoporotic fractures, 277, 348
- Osteosarcomas, 282
- P**
- p16* gene, 10, 13t, 15, 172
- p16<sup>ink4a</sup>* gene, 9, 30
- p53* gene, 9–14, 56, 99, 156, 176, 213



- Pain  
assessment of, 341–345  
management of, 346–349, 346f  
WHO ladder approach to pain relief, 346
- Papillary glioneuronal tumors, 30
- Papovavirus infection, 306
- Paragangliomas, 25, 32, 50, 316, 318
- Parasitic infections, 300t, 302t
- Pars intermedia cysts, 218
- Pediclectomy, use during surgery, 291
- Pegvisomant, 57, 205
- PEP-3 vaccination, 185
- Percutaneous needle vertebral augmentation, 289
- Perfusion imaging, 40–41, 47
- P-glycoprotein, 155
- Phenobarbital, 156
- Phenytoin, 156, 335
- Phosphatase and tensin homolog (*PTEN*) gene, 10, 30, 156, 159, 174, 177
- PI3K/AKT axis, 174, 175f, 177
- Pituitary adenomas, 39f, 146–147, 192–194, 194t, 201f, 205f, 210, 211f, 215, 216f, 218
- Pituitary gland, 196, 203, 205, 208–209, 212, 218–220  
compression of, 194–195, 210, 218  
enlargement of, 210  
metastases to, from systemic cancer, 215–218
- Pituitary metastases, 215, 216
- Pituitary tumors, 7  
clinical presentation of, 194–197  
laboratory investigation of, 197–198  
malignant, 212–215  
pathology of, 193–194  
radiologic evaluation of, 198–199  
syndromes of, 219–220  
treatment for, 146–147, 199–212
- Plasma cell neoplasms, 281
- Plasmacytomas, 281
- Platelet-derived growth factor (PDGF), 57–58, 86, 172, 174, 176–177
- Pleomorphic xanthoastrocytomas (PXAs), 30, 32, 94–95, 109–110, 113, 115
- Pneumocystis, 306
- Polyarteritis nodosa, 303t
- Poly-ICLC vaccination, 185
- Positron emission tomography, 48–49, 67, 149, 227, 277, 305
- PRECISE trial, 162
- Prednisone, use in treating PCNSL, 266
- Primary central nervous system lymphoma (PCNSL)  
AIDS-related, 264–265  
diagnosis and staging of, 264–265, 265t, 266f  
salvage treatment for, 270–271  
treatment for, 266–270, 268f
- Primitive neuroectodermal tumors (PNETs), 7t, 8, 19, 143–144
- Procarbazine, 107, 163, 165, 173, 267–270
- Procarbazine, CCNU, and vincristine (PCV), 107–108, 116, 161, 163–166, 173
- Progressive systemic sclerosis, 303t
- Prolactin, 193–197, 214
- Prolactin-secreting adenomas, 196, 199, 202–204, 212–213, 219
- Proliferation markers, 29
- Prophylactic cranial irradiation (PCI), use in treating lung cancer brain metastases, 233
- Prostate cancer, 286–287
- Pseudomonas* exotoxin, use in treating gliomas, 179
- PTEN/MMAC tumor suppressor, 177
- PTK787 compound, use in treating gliomas, 177

**Q**

## Quality of life

- assessment of, 336
- variables contributing to, 106, 187, 254, 259, 285

**R**RAD001, *See* Rapamycin

## Radiation, effect on tumor

- incidence, 13t, 15–17, 56

## Radiation Therapy Oncology Group

- (RTOG), 107–108, 108t, 142t, 157, 164–166, 228, 266–267

## Radionuclide bone scanning, 277, 280

## Radiotherapy, 63–66, 81, 86,

- 115–116, 125, 132, 141–145, 173, 203–206, 209–210, 214, 254, 266, 282, 285, 291

## adjuvant, 63–66, 86, 88, 145, 291, 315, 324

## adverse effects of, 147–149

## benign tumors, role in, 145–147

## brachytherapy, 140, 141f, 142–143

## classic 3-dimensional, 137

## conformal, 136–137, 196

## CyberKnife radiosurgery, 138

## external-beam, 64–65, 80–81, 125, 160, 165, 203, 217, 254–255, 291

## fractionated stereotactic, 72–73, 146

## Gamma Knife radiosurgery, 65, 71–72, 74, 88, 138, 203, 234

## intensity-modulated (IMRT), 65–66, 141, 139

## linear accelerator (LINAC)-based radiosurgery, 65, 88, 138

## of low-grade gliomas, 104–106, 105t

## malignant tumors, role in, 141–145

## proton therapy, 138, 140–141, 144, 147

- radiosurgery, 65, 71–73, 76, 88–89, 138–139, 144–145, 203
- stereotactic radiosurgery (SRS), 65, 71–73, 138–139, 203, 226
- tomotherapy system, 139
- whole-brain (WBRT), 226, 230–235, 237, 240, 266–268, 339

## Rapamycin (RAD001), use in treating gliomas, 177

*ras* gene, 58

## Ras/MEK/ERK pathway, 174, 175f

## Response Evaluation Criteria in Solid Tumors (RECIST), 157

Retinoblastoma (*Rb*) gene, 13t, 238

## Rheumatoid arthritis, 301–302t, 304, 325t

## Rituximab, use in treating PCNSL, 268, 270–271

## Rosette glioneuronal tumors, 30

**S**

## Sarcotomy, 280, 291

## Sarcoidosis, 79, 299, 302t, 304, 306, 318, 325t

## Schistosomiasis, 304, 306

## Schwannomas, 11–12, 25, 75f, 317, 319

## of the cranial nerves, 73–77

## facial nerve, 74, 75f

## jugular foramen, 75–77, 76f, 76t

## trigeminal, 73–74, 73f

## vestibular, 67–73, 69–70f, 72f

## Sella turcica, cystic lesions of, 217–219

## Signal transducers and activators of transcription (STAT), 174, 178

## Sjögren's syndrome, 301–302t, 304, 306, 325t

## Small cell lung carcinoma (SCLC), 232–233, 236, 246, 251f, 259, 286, 291

## SMARCB2 gene, 56

## Southwest Oncology Group (SWOG), 160, 165–166

- Spastic paraparesis, 302t, 306  
 Squamous cell carcinoma, 233, 287  
 Steroids, 80, 147, 207, 226, 228, 230–233, 236, 264, 287, 306, 346  
 Subependymal giant cell astrocytomas (SEGAs), 32, 94–95, 109–110, 113, 115  
 Surgical resection, 227–228, 230–232, 234–235, 240  
 Surveillance, Epidemiology, and End Results (SEER) program, 3–6  
 SV40-contaminated polio vaccine, effect on cancer incidence, 20  
 SV-40 virus, role in choroid plexus papillomas, 84  
 Syphilis, 306, 325t  
 Systemic lupus erythematosus, 303t, 306, 325t
- T**
- Tabes dorsalis, 302t  
 Takayasu's arteritis, 303t  
 Tamoxifen, 57, 66, 160  
 Temozolomide, 108, 160–166, 173, 175–177, 240, 256, 268, 270–271  
 Temporal arteritis, 303t, 325t  
 Tenascin, use in treating gliomas, 172, 184  
 Teniposide, 161, 233  
 Thiotepe (triethylenethiophosphoramidate), 255–257, 269–270  
 Thoracic kyphotic deformities, 287  
 Thyrotropin (TSH), 193, 197, 213  
 Thyrotropin-secreting tumors, 194–195, 199, 209–210  
 Tinea capitis, 15, 56  
 Tinnitus, 68, 74, 249t  
 Topotecan, 161, 233, 256, 268, 270  
*Toxoplasma gondii*, as cause of meningiomas, 14, 20  
 TP53 gene, 30, 84, 159, 172
- Transsphenoidal surgery, 80, 200, 201f, 204, 205f, 208–210, 211f, 216f, 217–218, 217f  
 Trastuzumab, use in treating breast cancer brain metastases, 236–237  
 Trigeminal nerve deficits, 74  
 Tuberculosis, 299, 302t, 306, 318, 325t  
 Tuberos sclerosis, 13t, 14, 109  
 Tuberos sclerosis 2 (TSC2) gene, effect on ganglioglioma incidence, 11  
 Tumor, node, metastases (TNM) schema, 236
- U**
- Ultrasonography, intraoperative, 102, 104, 126, 128–129, 230, 310  
 Ultraviolet light and malignant melanoma, 238
- V**
- Vaccination, 185–186  
 Valsalva maneuver, use during surgery, 129  
 Varicella zoster virus (VZV), 14, 20, 301–302t, 306, 325t  
 Vascular endothelial growth factor (VEGF), 58, 86–87, 176–177  
 Vasculitis, 40, 306  
 Venography, 38–40, 42  
 Vertebrectomy, 290–291  
 Vertebroplasty, 281, 289–290, 289f, 348  
 Vertigo, 68, 74, 249t  
 Vincristine, use in treating PCNSL, 266–267, 269–270  
 von Hippel-Lindau (VHL) disease, 86–89, 308
- W**
- Warburg effect, 179  
 Wegener's granulomatosis, 302t, 325t

- Wernicke's speech area, 128
- Wisconsin Brief Pain Inventory (BPI), 342
- Wong-Baker FACES pain rating scale, 344, 344f
- World Health Organization (WHO) classification system, 25, 158t, 346f
- and astrocytomas, 141, 143, 145
- and choroid plexus papillomas, 84
- and gliomas, 94–95, 98–99, 101, 107–108, 113, 154, 158, 166
- and meningiomas, 58, 61–62, 64
- WP1066 compound, use in treating gliomas, 178